Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Total Assets

Everything the company owns or controls; equal to total liabilities plus equity.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Total Assets · Q1 FY2026 · quarter ended Mar 2026

Total assets falls 24.2% from a year ago

Total assets stood at $183.97M at the end of Q1 FY2026, down 24.2% from a year earlier and up 25.6% from the prior quarter. Over 3 fiscal years it compounded at -20.4% a year.

Context

  • Total assets increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total assets keeps falling in the next quarterly balance sheet after a -24.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$183.97M+25.6% QoQ
Last fiscal yearDec 2025
$146.48M-19.0% YoY
Year agoMar 2025
$242.64M-24.2% since
Total Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.2%——
1 year-19.0%——
3-year CAGR-20.4%——
5-year CAGR——
10-year CAGR——

Total Assets history

USD · from the balance sheet

Latest · FY2025
146.48M USD
Year-over-year change
-19.0%
4-year CAGR
-0.7%

Total Assets vs competitors

How INBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -24.2% is the lowest of 6, against a peer median of -15.3%.
  • Over three fiscal years its annual growth of -20.4% compares with a peer median of +18.2%.
INBX Competitors
Total Assets for INBX and competitors
Company Period Latest balance YoY 3-year CAGR
JANXJanux Therapeutics, Inc.Mar 2026$1.03B USD-2.1%+40.4%
CLDXCelldex Therapeutics, Inc.Sep 2026$721.53M USD+11.3%+18.2%
GENBGenerate Biomedicines, Inc.Mar 2026$625.74M USD——
IMTXImmatics N.V.Mar 2026€543.83M EUR-15.3%+11.3%
TECXTectonic Therapeutic, Inc.Mar 2026$246.58M USD-21.7%+76.8%
ABSIAbsci CorporationMar 2026$195.59M USD-15.9%-12.3%
INBXInhibrx Biosciences, Inc.Mar 2026$183.97M USD-24.2%-20.4%
Peer median (excluding INBX) —-15.3%+18.2%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents131.3M273.87M277.92M152.6M124.22M
Short-term Investments00000
Net Receivables878K257K778K420K177K
Inventory(878K)0000
Other Current Assets7.81M181K728K816K238K
Total Current Assets139.11M280.49M295.36M160.4M132.83M
Property, Plant & Equipment (Net)9.49M7.22M9.37M13.54M9.27M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.85M3.16M3.16M6.83M4.38M
Total Non-current Assets11.34M10.38M12.54M20.37M13.65M
Total Assets150.45M290.88M307.89M180.77M146.48M
Account Payables9.13M8.33M10.95M9.25M5.94M
Short-term Debt1.67M1.86M01.6M2.33M
Tax Payables00000
Deferred Revenue2.03M166K000
Other Current Liabilities9.62M13.85M6.51M7.73M18.08M
Total Current Liabilities22.45M27.58M56.31M40.73M33.8M
Long-term Debt70.47M202.07M206.97M0100.56M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)110K0000
Other Non-current Liabilities5.03M0000
Total Non-current Liabilities75.61M205.24M208.08M6.45M104.69M
Total Liabilities98.07M232.82M264.39M47.18M138.49M
Common Stock4K4K5K1K1K
Retained Earnings(227.15M)(372.37M)(613.73M)(106.13M)(246.19M)
Accumulated OCI(150.45M)0000
Other Stockholders Equity279.53M0000
Minority Interest00000
Total Equity52.38M58.06M43.5M133.58M7.99M
Total Debt72.14M207.1M210.14M8.05M107.01M
Net Debt(59.16M)(66.76M)(67.78M)(144.55M)(17.21M)

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.